🇺🇸 FDA
Company

Inhibikase

Inhibikase Therapeutics

IKT biotech USA

Quick answer

Inhibikase is a biotech company (IKT) headquartered in WILMINGTON, DE, USA with 3 tracked pipeline programs.

Pipeline (3)

project

IKT-001

Pulmonary Arterial Hypertension

Phase 3 · small_molecule · active

1 trials project

IkT-001Pro

Pulmonary Arterial Hypertension (PAH)

Phase 2 · small_molecule · terminated

1 trials project

Imatinib Mesylate

CML

Phase 1 · small_molecule · completed

1 trials

Patents (8)

patent

US 11725005

Compositions and methods for inhibiting kinases

Expires Mon Aug 10 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11407747

Compositions and methods for inhibiting kinases

Expires Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 10906896

Compositions and methods for inhibiting kinases

Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 10344027

Compositions and methods for inhibiting kinases

Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 10316031

Compositions and methods for inhibiting kinases

Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 10118923

Compositions and methods for inhibiting kinases

Expires Mon Nov 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 9907796

Methods of treating tumoral diseases, or bacterial or viral infections

Expires Mon Mar 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 9828370

Compositions and methods for inhibiting kinases

Expires Mon Nov 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)